Date: XX/XXX/XXXX

GP Name and Address:

Patient name: \_\_\_\_\_\_\_\_\_\_\_\_ Local Hospital No: \_\_\_\_\_\_\_\_\_\_ NHS No: \_\_\_\_\_\_\_\_\_\_\_\_\_\_

Patient address: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Dear Dr

**RE: Participant in Beta-blockers or Placebo in patients with portal hypertension (BOPPP) study. A blinded, multi-centre, clinical effectiveness and cost-effectiveness randomised controlled trial.**

I am writing to inform you that this patient has been a participant in the BOPPP study for the last X years. During that time they received carvedilol OR placebo and were followed up by the trial team. They are now leaving the study, their present Child Pugh grade is A/B/C.

On the basis of their most recent endoscopy, present guidance suggests to start carvedilol/observe without use of carvedilol. Cessation of carvedilol in those patients who received active medication is not expected to be detrimental and so only patients who require beta-blockade for clinical reasons should continue. The BOPPP study will report over the next few months and further guidance may be issued. Any updates can be found on the BOPPP Trial website: [www.BOPPP-trial.org](http://www.BOPPP-trial.org). Alternatively, for further information please email the Central BOPPP Trial Management Team on:

kch-tr.boppptrial@nhs.net.

We are grateful for your continued care of this patient. If you have any further questions please do not hesitate to contact us.

Yours sincerely,

Dr XXXXX XXXXX

Principal Investigator